A Global Leader In Integrated CDMO Services

Organizations developing modern therapeutics increasingly rely on partners capable of supporting complexity across discovery, development, and commercialization. This overview highlights a global CDMO infrastructure built to streamline that journey, backed by 9,000 employees and 4,600 R&D scientists who help teams progress from early route design to large‑scale GMP production. Capabilities span small‑molecule CMC programs, biologics, peptides, oligonucleotides, and advanced modalities, supported by proven regulatory strength—demonstrated through 100+ successful inspections across major authorities.

Specialized platforms, including continuous manufacturing, enzyme engineering, and flow chemistry, help reduce development risks and improve scalability. Integrated preclinical, clinical, and commercial services offer consistent quality and clear pathways from IND to NDA.

Readers will gain insight into how a unified global network, deep technical expertise, and extensive GMP capacity can accelerate timelines while supporting long‑term lifecycle management. Access the full asset to explore detailed capabilities, capacity breakdowns, and technology platforms.